ISSN: 0264-410X
Journal Home
Journal Guideline
Vaccine Q1 Unclaimed
Vaccine is a journal indexed in SJR in Infectious Diseases and Molecular Medicine with an H index of 215. It has a price of 2395 €. It has an SJR impact factor of 1,342 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,342.
Vaccine focuses its scope in these topics and keywords: vaccine, influenza, vaccination, virus, recombinant, vaccines, immunization, protein, responses, immunogenicity, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2395 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,342
SJR Impact factor215
H Index971
Total Docs (Last Year)3134
Total Docs (3 years)37603
Total Refs13164
Total Cites (3 years)2864
Citable Docs (3 years)4.47
Cites/Doc (2 years)38.73
Ref/DocOther journals with similar parameters
Nature Reviews Microbiology Q1
Clinical Microbiology Reviews Q1
The Lancet Infectious Diseases Q1
Cellular and Molecular Immunology Q1
Drug Resistance Updates Q1
Compare this journals
Aims and Scope
Best articles by citations
Alkyl-polyacrylate esters are strong mucosal adjuvants
View moreThe influence of host factors and immunogenetics on lymphocyte responses to HepageneS vaccination
View moreA look at new models to support vaccine research and development
View moreTeenagers' lifestyle and the risk of exposure to hepatitis B virus
View morePredictive value of pre-clinical work for vaccine safety assessment
View moreRational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids*1
View moreMaternal immunization: the influence of liability issues on vaccine development
View moreAnalysis of factors influencing vaccine uptake from various perspectives
View moreAnalysis of factors influencing vaccine uptake: perspective from Spain
View moreAnalysis of factors influencing vaccine uptake: perspectives from Belgium
View moreRegulating vaccines involving new technologies to ensure safety and timely licensure - the challenge
View morePneumococcal infections in New Zealand
View moreThe antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens
View moreEfficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply
View moreInduction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model
View moreInduction of mucosal immunity with a replication-defective adenoviral recombinant
View moreDNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development
View moreThe medical scientist working with the media for the public good
View moreHow to improve communication on vaccine issues at the national level?
View moreHow to improve communication on vaccine safety at international level?
View moreStatistical assessment of the association between vaccination and rare adverse events post-licensure
View moreBooster vaccination with recombinant hepatitis B vaccine four years after priming with one single dose
View morePre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization
View morePerception of risk of vaccine adverse events: a historical perspective
View more
Comments